Bone involvement and osteoporosis in mastocytosis

Immunol Allergy Clin North Am. 2014 May;34(2):383-96. doi: 10.1016/j.iac.2014.01.011. Epub 2014 Mar 13.

Abstract

Bone involvement is frequent in patients with systemic mastocytosis. Osteoporosis is the most prevalent bone manifestation, but diffuse osteosclerosis or focal osteolytic or osteosclerotic lesions are not infrequent. The risk of osteoporotic fractures is high, especially at the spine and in men. Routine measurements of bone mineral density and vertebral morphometry are warranted. The bone turnover markers indicate the involvement of complex bone metabolism in mastocytosis-related manifestations. Bisphosphonates represent the first-line treatment for osteoporosis-related mastocytosis.

Keywords: Bone mineral density; Bone turnover markers; Fracture; Mastocytosis; Osteoporosis; Osteosclerosis.

Publication types

  • Review

MeSH terms

  • Adult
  • Bone Density
  • Bone Density Conservation Agents / therapeutic use
  • Clinical Trials as Topic
  • Diphosphonates / therapeutic use
  • Female
  • Humans
  • Male
  • Mastocytosis, Systemic / complications
  • Mastocytosis, Systemic / drug therapy
  • Mastocytosis, Systemic / epidemiology
  • Mastocytosis, Systemic / pathology*
  • Middle Aged
  • Osteoporosis / complications
  • Osteoporosis / drug therapy
  • Osteoporosis / epidemiology
  • Osteoporosis / pathology*
  • Spine / pathology*

Substances

  • Bone Density Conservation Agents
  • Diphosphonates